摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[(3S)-3-amino-3-carboxypropyl][(4-methoxy-3-nitrophenyl)hydroxymethyl]phosphinic acid | 936234-60-5

中文名称
——
中文别名
——
英文名称
[(3S)-3-amino-3-carboxypropyl][(4-methoxy-3-nitrophenyl)hydroxymethyl]phosphinic acid
英文别名
LSP1-2101;(3S)-3-[(((3-amino-3-carboxy)propyl)(hydroxy)phosphinyl)-hydroxymethyl]-3-nitro-4-methoxybenzene;(2S)-2-amino-4-[hydroxy-[hydroxy-(4-methoxy-3-nitrophenyl)methyl]phosphoryl]butanoic acid
[(3S)-3-amino-3-carboxypropyl][(4-methoxy-3-nitrophenyl)hydroxymethyl]phosphinic acid化学式
CAS
936234-60-5
化学式
C12H17N2O8P
mdl
——
分子量
348.249
InChiKey
HSHWJQGGJKYMDI-KBPLZSHQSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -3.6
  • 重原子数:
    23
  • 可旋转键数:
    7
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    176
  • 氢给体数:
    4
  • 氢受体数:
    9

反应信息

  • 作为反应物:
    描述:
    [(3S)-3-amino-3-carboxypropyl][(4-methoxy-3-nitrophenyl)hydroxymethyl]phosphinic acid盐酸 作用下, 以 为溶剂, 生成 [(3S,1'R)-3-amino-3-carboxypropyl][(4-methoxy-3-nitrophenyl)hydroxymethyl]phosphinic acid hydrochloride 、 [(3S,1'S)-3-amino-3-carboxypropyl][(4-methoxy-3-nitrophenyl)hydroxymethyl]phosphinic acid hydrochloride
    参考文献:
    名称:
    [EN] DIASTEREOISOMERS OF HYPOPHOSPHOROUS ACID DERIVATIVES
    [FR] DIASTÉRÉOISOMÈRES DE DÉRIVÉS D'ACIDE HYPOPHOSPHOREUX
    摘要:
    该发明涉及具有式(I)的次磷酸衍生物的对映异构体,其中苯基被一个或多个原子或基团取代,占据苯环上的一个或多个位置,并提供了一种分离它们的方法。
    公开号:
    WO2010106526A1
  • 作为产物:
    描述:
    [(3S)-3-(N-benzyloxycarbonyl)amino-3-methoxycarbonylpropyl][(4-methoxy-3-nitrophenyl)hydroxymethyl]phosphinic acid盐酸 作用下, 反应 5.0h, 以304 mg的产率得到[(3S)-3-amino-3-carboxypropyl][(4-methoxy-3-nitrophenyl)hydroxymethyl]phosphinic acid
    参考文献:
    名称:
    Increased Potency and Selectivity for Group III Metabotropic Glutamate Receptor Agonists Binding at Dual sites
    摘要:
    A group III metabotropic glutamate (mGlu) receptor agonist (PCEP) was identified by virtual HTS. This orthosteric ligand is composed by an L-AP4-derived fragment that mimics glutamate and a chain that binds into a neighboring pocket, offering possibilities to improve affinity and selectivity. Herein we describe a series of derivatives where the distal chain is replaced by an aromatic or heteroaromatic group. Potent agonists were identified, including some with a mGlu(4) subtype preference, e.g., 17m (LSP1-2111) and 16g (LSP4-2022). Molecular modeling suggests that aromatic functional groups may bind at either one of the two chloride regulatory sites. These agonists may thus be considered as particular bitopic/dualsteric ligands. 17m was shown to reduce GABAergic synaptic transmission at striatopallidal synapses. We now demonstrate its inhibitory effect at glutamatergic parallel fiber-Purkinje cell synapses in the cerebellar cortex. Although these ligands have physicochemical properties that are markedly different from typical CNS drugs, they hold significant therapeutic potential.
    DOI:
    10.1021/acs.jmedchem.7b01438
点击查看最新优质反应信息

文献信息

  • Hypophosphorous Acid Derivatives and their Therapeutical Applications
    申请人:Acher Francine
    公开号:US20090170813A1
    公开(公告)日:2009-07-02
    Hypophosphorous acid derivatives having Formula (I) wherein .M is a [C(R3,R4)]n1-C(E,COOR1,N(H,Z)) group, or an optionally substituted Ar—CH(COOR1,N(H,Z)) group, or an a, β, or a β, g-cyclic amino acid; .R 1 is H or R, R being an hydroxy or a carboxy protecting group; .Z is H or an amino protecting group R′, benzyl oxycarbonyl, benzyl or benzyl substituted; .E is H or a C1-C3 alkyl, aryl, an hydrophobic group; .R 2 is selected in the group comprising: D-CH(R 6 )—C—(R 7 ,R 8 ), (R 11 ,R 12 )CH—C(R 9 ,R 10 ), D-CH(OH), D-[C(R 13 ,R 14 )] n3 —, C[(R 15 ,R 16 ,R 17 )] n4 , D-CH 2 , (R 18 )CH═C(R 19 ), D-(M 1 ) n6 —CO, Formula (II), PO(OH) 2 —CH 2 or (PO(OH) 2 —CH 2 ), (COOH—CH 2 )—CH 2 , with -D=H, OH, OR, (CH 2 ) n2 OH, (CH 2 ) n1 OR, COOH, COOR, (CH 2 ) n2 COOH, (CH 2 ) n1 COOR, SR, S(OR), SO 2 R, NO 2 , heteroaryl, C 1 -C 3 alkyl, cycloalkyl, heterocycloalkyl, (CH 2 ) n2 -alkyl, (COOH,NH 2 )—(CH 2 ) u1 -cyclopropyl-(CH 2 ) u2 —, CO—NH-alkyl, Ar, (CH 2 ) n2 —Ar, CO—NH—Ar; —R 3 to R 19 being H, OH, OR, (CH 2 ) n2 OH, (CH 2 ) n1 OR, COOH, COOR, (CH 2 ) n2 COOH, (CH 2 ) n1 COOR, C 1 -C 3 alkyl, cycloalkyl, (CH 2 )n1-alkyl, aryl, (CH 2 )n1-aryl, halogen, CF 3 , SO 3 H, (CH 2 ) x PO 3 H 2 , with x=0, 1 or 2, B(OH) 2 , Formula (III), NO 2 , SO 2 NH 2 , SO 2 NHR; SR, S(O)R, SO 2 R, benzyl; -M 1 is an alkylene or arylene group; -n1=1, 2 or 3, n2=1, 2 or 3, n3=0, 1, 2 or 3 and n4=1, 2 or 3, n5=1, 2 or 3, n6=0 or 1, u1 and u2, identical or different=0, 1 or 2, with the proviso that Formula (I) does not represent the racemic (3R,S) and the enantiomeric form (3R) of 3 amino,3-carboxy-propyl-2′-carboxy-ethylphosphinic acid; 3 amino,3-carboxy-propyl-4′carboxy,2′carboxy-butanoylphosphinic acid; 3 amino,3-carboxy-propyl-2′carboxy-butanoylphosphinic acid; 3 amino,3-carboxy-propyl-3′amino, 3′carboxy-propylylphosphinic acid; and 3 amino,3-carboxypropyl-7′amino-2′, 7′-dicarboxyheptylphosphinic acid, said hypophosphorous acid derivatives being diasteroisomers or enantiomers. Application as drugs.
    含有Formula (I)的次磷酸衍生物,其中.M是[C(R3,R4)]n1-C(E,COOR1,N(H,Z))基团,或者是一个可选择取代的Ar—CH(COOR1,N(H,Z))基团,或者是α,β或αβ,γ-环氨基酸;.R1是H或R,R是一个羟基或羧基保护基团;.Z是H或氨基保护基团R′,苄氧羰基,苄基或苄基取代;.E是H或C1-C3烷基,芳基,疏水基团;.R2是从以下群体中选择的:D-CH(R6)—C—(R7,R8),(R11,R12)CH—C(R9,R10),D-CH(OH),D-[C(R13,R14)]n3—,C[(R15,R16,R17)]n4,D-CH2,(R18)CH═C(R19),D-(M1)n6—CO,Formula (II),PO(OH)2—CH2或(PO(OH)2—CH2),(COOH—CH2)—CH2,其中-D=H,OH,OR,(CH2)n2OH,(CH2)n1OR,COOH,COOR,(CH2)n2COOH,(CH2)n1COOR,SR,S(OR),SO2R,NO2,杂环芳基,C1-C3烷基,环烷基,杂环烷基,(CH2)n2-烷基,(COOH,NH2)—(CH2)u1-环丙基-(CH2)u2—,CO—NH-烷基,Ar,(CH2)n2—Ar,CO—NH—Ar;—R3到R19为H,OH,OR,(CH2)n2OH,(CH2)n1OR,COOH,COOR,(CH2)n2COOH,(CH2)n1COOR,C1-C3烷基,环烷基,(CH2)n1-烷基,芳基,(CH2)n1-芳基,卤素,CF3,SO3H,(CH2)xPO3H2,其中x=0,1或2,B(OH)2,Formula (III),NO2,SO2NH2,SO2NHR;SR,S(O)R,SO2R,苄基;-M1是一个烷基或芳基基团;-n1=1,2或3,n2=1,2或3,n3=0,1,2或3,n4=1,2或3,n5=1,2或3,n6=0或1,u1和u2,相同或不同=0,1或2,但Formula (I)不代表3-氨基,3-羧基-丙基-2′-羧基-乙磷酸的消旋体(3R,S)和对映体形式(3R);3-氨基,3-羧基-丙基-4′羧基,2′羧基-丁酰磷酸;3-氨基,3-羧基-丙基-2′羧基-丁酰磷酸;3-氨基,3-羧基-丙基-3′氨基,3′羧基-丙基磷酸;和3-氨基,3-羧基丙基-7′氨基-2′,7′-二羧基庚基磷酸,所述的次磷酸衍生物为二对映异构体或对映体。用作药物的应用。
  • DIASTEREOISOMERS OF HYPOPHOSPHOROUS ACID DERIVATIVES
    申请人:Acher Francine
    公开号:US20120016155A1
    公开(公告)日:2012-01-19
    The invention relates to the diastereoisomers of hypophosphorous acid derivatives, having formula (I), wherein the phenyl group is substituted by one or several atoms or groups, occupying one or several positions on the phenyl ring, and a method for the separation thereof.
  • [EN] HYPOPHOSPHOROUS ACID DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS<br/>[FR] DERIVES ACIDES HYPOPHOSPHORES ET APPLICATIONS THERAPEUTIQUES
    申请人:CENTRE NAT RECH SCIENT
    公开号:WO2007052169A2
    公开(公告)日:2007-05-10
    [EN] Hypophosphorous acid derivatives having Formula (I) wherein . M is a [C(R3,R4)]n1 - C(E,COOR1, N(H, Z)) group, or an optionally substituted Ar-CH(COOR1, N(H, Z)) group, or an a, ß, or a ß, g-cyclic aminoacid; . R1 is H or R, R being an hydroxy or a carboxy protecting group; . Z is H or an amino protecting group R', benzyl oxycarbonyl, benzyl or benzyl substituted; . E is H or a C1-C3 alkyl, aryl, an hydrophobic group; . R2 is selected in the group comprising: D-CH(R6)- C-(R7, R8), (R11,R12)CH- C(R9, R10), D - CH(OH), D- [C(R13, R14)]n3 -, C[(R15, R16, R17)]n4, D-CH2, (R18)CH = C(R19), D-(M1)n6-CO, Formula (II), PO(OH)2-CH2 or (PO(OH)2-CH2), (COOH-CH2)-CH2, with - D = H, OH, OR, (CH2)n2OH, (CH2)n1OR, COOH, COOR, (CH2)n2COOH, (CH2)n1COOR, SR, S(OR), SO2R, NO2, heteroaryl, C1-C3 alkyl, cycloalkyl, heterocycloalkyl, (CH2)n2-alkyl, (COOH, NH2)-(CH2)u1-cyclopropyl-(CH2)u2-, CO-NH-alkyl, Ar, (CH2)n2-Ar, CO-NH-Ar; - R3 to R19 being H, OH, OR, (CH2)n2OH, (CH2)n1OR, COOH, COOR, (CH2)n2COOH, (CH2)n1COOR, C1-C3 alkyl, cycloalkyl, (CH2)n1-alkyl, aryl, (CH2)n1-aryl, halogen, CF3, SO3H, (CH2)x PO3H2, with x = 0, 1 or 2, B(OH)2 , Formula (III), NO2 , SO2NH2 , SO2NHR; SR, S(O)R, SO2R, benzyl; - M1 is an alkylene or arylene group; - n1= 1, 2 or 3, n2= 1, 2 or 3, n3= 0, 1, 2 or 3 and n4= 1, 2 or 3, n5= 1,2 or 3, n6= 0 or 1, u1 and u2, identical or different = 0,1 or 2, with the proviso that Formula (I) does not represent the racemic (3R, S) and the enantiomeric form (3R) of 3 amino,3-carboxy-propyl-2'-carboxy-ethylphosphinic acid; 3 amino,3-carboxy-propyl- 4'carboxy,2'carboxy-butanoylphosphinic acid; 3 amino,3-carboxy-propyl- 2'carboxy-butanoylphosphinic acid; 3 amino,3-carboxy-propyl- 3'amino, 3'carboxy-propylylphosphinic acid; and 3 amino,3-carboxypropyl -7'amino-2', 7'-dicarboxyheptylphosphinic acid, said hypophosphorous acid derivatives being diasteroisomers or enantiomers. Application as drugs.
    [FR] Cette invention concerne des dérivés acides hypophosphorés représentés par la formule (I). Dans cette formule, M est un groupe [C(R3,R4)]n1 - C(E,COOR1, N(H, Z)), ou un groupe Ar-CH(COOR1, N(H, Z)) éventuellement substitué, ou un acide aminé a, ß, ou g-cyclique; . R1 est H ou R, R étant un groupe protecteur hydroxy ou carboxy; . Z est H ou un groupe amino protecteur R', benzyl oxycarbonyl, benzyle ou substitué benzyle; E est H ou un C1-C3 alkyle, aryle, un groupe hydrophobe; . R2 est pris dan le groupe comprenant: D-CH(R6)- C-(R7, R8), (R11,R12)CH- C(R9, R10), D - CH(OH), D- [C(R13, R14)]n3 -, C[(R15, R16, R17)]n4, D-CH2, (R18)CH = C(R19), D-(M1)n6-CO, PO(OH)2-CH2 ou (PO(OH)2-CH2), (COOH-CH2)-CH2, avec - D = H, OH, OR, (CH2)n2OH, (CH2)n1OR, COOH, COOR, (CH2)n2COOH, (CH2)n1COOR, SR, S(OR), SO2R, NO2, hétéroaryle, C1-C3 alkyle, cycloalkyle, hétérocycloalkyle, (CH2)n2-alkyle, (COOH, NH2)-(CH2)u1-cyclopropyl-(CH2)u2-, CO-NH-alkyle, Ar, (CH2)n2-Ar, CO-NH-Ar; - R3 à R19 étant H, OH, OR, (CH2)n2OH, (CH2)n1OR, COOH, COOR, (CH2)n2COOH, (CH2)n1COOR, C1-C3 alkyle, cycloalkyle, (CH2)n1-alkyle, aryle, (CH2)n1-aryle, halogène, CF3, SO3H, (CH2)x PO3H2, avec x = 0, 1 ou 2, B(OH)2,, NO2, SO2NH2, SO2NHR; SR, S(O)R, SO2R, benzyle; - M1 est un groupe alkylène ou arylène; - n1= 1, 2 ou 3, n2= 1, 2 ou 3, n3= 0, 1, 2 ou 3 et n4= 1, 2 ou 3, n5= 1,2 ou 3, n6= 0 or 1, u1 and u2, identiques ou différents = 0,1 ou 2, à condition quela formule (I) ne représenter pas la forme racémique (3R, S) ni la forme énantiomère (3R) de 3 amino,3-carboxy-propyl-2'-carboxy-éthylphosphinique acide; 3 amino,3-carboxy-propyl- 4'carboxy,2'carboxy-butanoylphosphinique acide; 3 amino,3-carboxy-propyl- 2'carboxy-butanoylphosphinique acide; 3 amino,3-carboxy-propyl- 3'amino, 3'carboxy-propylylphosphinique acide; and 3 amino,3-carboxypropyl -7'amino-2', 7'-dicarboxyheptylphosphinique acide, lesdits dérivées acides hypophosphorés étant des diastero-isoméres ou des énantiomères. Cette invention concerne également l'application de ces dérivés en tant que médicaments.
  • Increased Potency and Selectivity for Group III Metabotropic Glutamate Receptor Agonists Binding at Dual sites
    作者:Chelliah Selvam、Isabelle A. Lemasson、Isabelle Brabet、Nadia Oueslati、Berin Karaman、Alexandre Cabaye、Amélie S. Tora、Bruno Commare、Tiphanie Courtiol、Sara Cesarini、Isabelle McCort-Tranchepain、Delphine Rigault、Laetitia Mony、Thomas Bessiron、Heather McLean、Frédéric R. Leroux、Françoise Colobert、Hervé Daniel、Anne Goupil-Lamy、Hugues-Olivier Bertrand、Cyril Goudet、Jean-Philippe Pin、Francine C. Acher
    DOI:10.1021/acs.jmedchem.7b01438
    日期:2018.3.8
    A group III metabotropic glutamate (mGlu) receptor agonist (PCEP) was identified by virtual HTS. This orthosteric ligand is composed by an L-AP4-derived fragment that mimics glutamate and a chain that binds into a neighboring pocket, offering possibilities to improve affinity and selectivity. Herein we describe a series of derivatives where the distal chain is replaced by an aromatic or heteroaromatic group. Potent agonists were identified, including some with a mGlu(4) subtype preference, e.g., 17m (LSP1-2111) and 16g (LSP4-2022). Molecular modeling suggests that aromatic functional groups may bind at either one of the two chloride regulatory sites. These agonists may thus be considered as particular bitopic/dualsteric ligands. 17m was shown to reduce GABAergic synaptic transmission at striatopallidal synapses. We now demonstrate its inhibitory effect at glutamatergic parallel fiber-Purkinje cell synapses in the cerebellar cortex. Although these ligands have physicochemical properties that are markedly different from typical CNS drugs, they hold significant therapeutic potential.
  • [EN] DIASTEREOISOMERS OF HYPOPHOSPHOROUS ACID DERIVATIVES<br/>[FR] DIASTÉRÉOISOMÈRES DE DÉRIVÉS D'ACIDE HYPOPHOSPHOREUX
    申请人:CENTRE NAT RECH SCIENT
    公开号:WO2010106526A1
    公开(公告)日:2010-09-23
    The invention relates to the diastereoisomers of hypophosphorous acid derivatives, having formula (I), wherein the phenyl group is substituted by one or several atoms or groups, occupying one or several positions on the phenyl ring, and a method for the separation thereof.
    该发明涉及具有式(I)的次磷酸衍生物的对映异构体,其中苯基被一个或多个原子或基团取代,占据苯环上的一个或多个位置,并提供了一种分离它们的方法。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐